STAT1 and neoplasm: Current studies have confirmed that STAT3-mediated inhibitory tumor immune response has an antagonistic effect on STAT1-driven antitumor immune response [19], which may lead to the loss of function of the IFNγ/JAK/STAT1 pathway.